From the Confidence Medical Affairs Desk by Katarina Nedman

Medical coding is often perceived as a technical or data management activity performed somewhere in the background of a clinical trial. In reality, coding decisions play a far more significant role. They directly influence how clinical data is interpreted, analyzed, and ultimately presented throughout the entire development program.

At its core, medical coding is not simply about assigning terms within MedDRA or WHO Drug dictionaries. It is about ensuring that the coded data accurately reflects the underlying clinical reality of the patient.

The principle is simple: how data is coded determines how it will be analyzed and ultimately how it will appear in the Clinical Study Report (CSR) and across the entire clinical program.

Because coding drives downstream analyses, even relatively small inconsistencies can create significant downstream consequences across the study and broader clinical development program. Inaccurate or inconsistent coding may affect:

• safety signal detection 
• incidence rate calculations 
• endpoint analyses 
• aggregate safety reviews 
• CSR interpretation 
• and ultimately program-level decision making

Importantly, these issues are not always caused by obvious errors. In many cases, they originate from subtle differences in interpretation between sites, reviewers, or coding approaches.

When Similar Clinical Events Are Coded Differently

One of the biggest challenges in medical coding is that similar clinical scenarios may be described very differently across sites. Without proper medical review and alignment, those differences can significantly alter how events are analyzed later.

For example, consider two patients with essentially the same clinical presentation:

A patient has ALT 6× ULN without symptoms.
One site reports the event as “ALT increased.”
Another site reports a similar isolated and asymptomatic ALT elevation as “hepatitis.”

Although the underlying clinical situation may be very similar, these events may ultimately contribute to entirely different safety analyses.

→ In the CSR, these events will not be grouped the same way.
→ One contributes to laboratory abnormalities, while the other contributes to hepatic adverse events.
→ As a result, the perceived incidence of liver injury may vary depending on coding, rather than the actual underlying clinical findings.

This distinction becomes especially important during aggregate safety review, where coding directly influences:

• severity interpretation 
• relatedness assessments 
• expectedness evaluations 
• and potential signal detection 

A case coded as “ALT increased” may be interpreted very differently from a case coded as “hepatitis” when assessing specificity, severity, or whether an event should be considered expected or unexpected.

The same type of issue frequently appears in concomitant medication indications and infection-related analyses.

A patient is treated for infection.
One site enters “antibiotic” as the indication for concomitant medication, another enters “respiratory infection,” while another records “fever.”

Without medical oversight, autocoding may classify these entries into entirely different concepts.

→ Autocoding may map these entries to unrelated categories.
→ Infection-related analyses can become fragmented, making potential safety signals more difficult to identify and interpret.

In practice, this fragmentation may affect:

• infection trend analyses 
• drug–drug interaction assessments 
• interruption pattern evaluations 
• and the ability to identify adverse events potentially associated with the investigational product 

Another common example involves interpretation of patient-reported symptoms.

A patient reports “chest discomfort.”
Without medical review, the term may simply be coded as chest pain.
However, with additional context, the event may actually represent angina or even myocardial infarction.

→ The difference is not semantic. It directly impacts SAE classification, medical review, and safety signal detection.

These examples highlight an important reality in clinical research. Dictionaries and autocoding alone cannot ensure clinically meaningful coding. Effective review requires medical interpretation and clinical judgment.

Why Medical Monitor Oversight Matters

Medical coding review requires substantially more than familiarity with coding dictionaries. It requires understanding the broader clinical context surrounding the patient, the study, and the event itself.

Although Medical Monitors should have advanced knowledge of MedDRA and WHO Drug coding principles, effective coding review also requires understanding:

• clinical context 
• coding hierarchies and preferred terms 
• multiaxial coding and how terms are analyzed 
• and the ability to validate unclear or inconsistent data through timely site queries 

This is where Medical Monitors play a critical role. Their responsibility is not simply to review coded terms, but to ensure that the data accurately reflects the clinical reality behind the event.

In many studies, Medical Monitors are uniquely positioned to:

• identify inconsistencies between medical history, adverse events, and concomitant medications 
• recognize when coding does not align with the clinical presentation 
• clarify ambiguous entries with sites 
• and maintain consistency across reviewers and study regions 

As clinical trials become larger and more globally distributed, maintaining this consistency becomes increasingly important.

The Risk of Inconsistency Across Multiple Reviewers

Studies involving multiple Medical Monitors often face an additional layer of complexity. Even when standardized coding dictionaries are used, interpretation differences between reviewers can still create variability across the dataset.

Without alignment, the same clinical scenario can be coded differently depending on who reviews it.

Over time, these inconsistencies can affect:

• grouped analyses 
• safety summaries 
• incidence calculations 
• narrative consistency 
• and ultimately the interpretation of study results within the CSR 

For this reason, operational alignment across reviewers is essential.

Defining a primary Medical Monitor, aligning on study-specific coding conventions, and reviewing those conventions regularly helps ensure consistency and protects overall data quality.

Regular calibration discussions, shared coding guidance, and ongoing communication between reviewers can significantly reduce downstream discrepancies and improve the overall reliability of study data.

However, even the strongest coding conventions have limitations if the original data collection process is poorly designed.

Coding Quality Begins at Data Entry

One of the most underestimated aspects of medical coding is that coding quality starts long before database lock. In many cases, the quality of the final coded dataset is largely determined by how the information was initially collected.

If the EDC allows unrestricted free-text entries such as “infection,” “pain,” or “treatment,” no coding convention can fully resolve that ambiguity downstream.

By the time inconsistencies are identified during coding review, substantial operational effort may already be required to clarify or reconcile the data.

This is why early Medical Monitor involvement during study setup is so valuable.

Early involvement of Medical Monitors during study setup allows for:

• structured fields instead of unrestricted free text 
• controlled terminology 
• logical links between Medical History, Adverse Events, and Concomitant Medications 
• and ultimately cleaner coding and more reliable downstream analyses 

Well-designed EDC structures reduce ambiguity at the source, improve operational efficiency, and help ensure that the coded data remains clinically meaningful throughout the study lifecycle.

Collaboration With Sponsors Is Equally Important

Coding decisions ultimately shape how data is interpreted and presented throughout the clinical development program. Because of this, close alignment between sponsors and study teams remains essential.

Coding decisions directly influence how data is presented and interpreted. Alignment ensures that what is coded reflects clinical reality, study intent, and regulatory expectations.

Strong collaboration between sponsors, Medical Monitors, clinical operations teams, and data management teams helps maintain consistency throughout the trial and supports more reliable clinical interpretation at the program level.

These challenges become even more apparent in large and operationally complex trials where coding review occurs late in the lifecycle. In the second article, we examine a real-world example that demonstrates how poor upstream data structure and delayed coding oversight can quickly turn medical coding into a major operational bottleneck.

Conclusion

Medical coding is not simply a technical exercise performed during study closeout. It is a continuous medical and operational responsibility that directly impacts safety evaluation, data integrity, and regulatory interpretation.

High-quality coding cannot be retrofitted at the end of a trial. It must be built into the study from the very beginning through thoughtful EDC design, aligned coding conventions, proper site training, and active Medical Monitor oversight throughout the clinical trial lifecycle.